Five Game-Changing Treatments for Kids: What Got FDA Approval in 2025

The Food and Drug Administration (FDA) approved several groundbreaking pediatric treatments in 2025, offering new hope for children with conditions ranging from severe allergies to rare genetic disorders. These approvals represent significant advances in childhood healthcare, providing safer, more effective options for young patients and their families.

What Makes These 2025 Approvals So Revolutionary?

The standout feature of 2025's pediatric approvals was their focus on addressing long-standing treatment gaps. Many of these medications became the first of their kind for children, offering alternatives where none existed before. The approvals span multiple medical areas, from infectious disease prevention to rare genetic conditions.

Among the most significant approvals was the needle-free epinephrine nasal spray called neffy, which received FDA approval on March 5, 2025, for children aged 4 years and older weighing 33 to 66 pounds. This became the first and only needle-free epinephrine treatment for younger children, expanding from its original approval for patients weighing at least 66 pounds.

Which Vaccines and Preventive Treatments Got Approved?

Several vaccine approvals marked major milestones in pediatric infectious disease prevention. The meningococcal ABCWY vaccine (Penmenvy) gained approval on February 15, 2025, for individuals aged 10 to 25 years. This vaccine targets five groups of Neisseria meningitidis bacteria that cause the most invasive meningococcal disease cases globally.

Another significant vaccine expansion came with MenQuadfi, which received approval on May 23, 2025, to include children as young as 6 weeks old. Originally approved in 2020 for individuals aged 2 years and older, this quadrivalent meningococcal vaccine now protects infants from invasive meningococcal disease caused by serogroups A, C, W, and Y.

For respiratory syncytial virus (RSV) protection, the FDA approved clesrovimab (Enflonsia) on June 9, 2025. This monoclonal antibody protects infants from RSV disease during their first RSV season, addressing a critical need for the youngest patients.

What About Treatments for Chronic Conditions?

The year brought several approvals for chronic pediatric conditions. Dupilumab (Dupixent) received approval on April 18, 2025, for treating chronic spontaneous urticaria in patients aged 12 years and older. This interleukin-4 and interleukin-13 inhibitor became the first targeted therapy for this condition in over a decade, designed for patients whose disease isn't adequately controlled with antihistamine treatment.

For skin conditions, roflumilast topical foam gained approval on May 22, 2025, to treat plaque psoriasis of the scalp and body in patients aged 12 years and older. Additionally, a groundbreaking gene therapy called prademagene zamikeracel (Zevaskyn) received approval on April 25, 2025, as the first autologous, gene-modified cell therapy for recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

The infectious disease treatment landscape also expanded with new options for urinary tract infections and sexually transmitted infections. Key approvals included:

• Gepotidacin (Blujepa): Approved March 25, 2025, for uncomplicated urinary tract infections in females aged 12 years and older weighing at least 40 kilograms, and later approved December 11, 2025, for uncomplicated urogenital gonorrhea
• Zoliflodacin (Nuzolvence): Approved December 12, 2025, as a single-dose oral treatment for uncomplicated urogenital gonorrhea in patients 12 years and older weighing at least 77 pounds
• Lenacapavir (Yeztugo): Approved June 18, 2025, as the first twice-yearly injectable pre-exposure prophylaxis for HIV prevention in adolescents and adults weighing at least 35 kilograms

"I think the value [of gepotidacin] for uncomplicated urinary tract infections is still really high. Because we have therapies that we can utilize, such as nitrofurantoin or fluoroquinolones, but at the same time, we've utilized those for a little while, and so individuals' antibiograms might show some type of resistance," said Ryan Haumschild, PharmD, vice president of pharmacy at Emory Healthcare and Winship Cancer Institute.

These 2025 approvals represent more than just new treatment options—they offer hope for families dealing with conditions that previously had limited or no pediatric-specific therapies. From eliminating the fear of needles in emergency allergy situations to providing the first gene therapy for a devastating skin condition, these treatments could fundamentally change how we approach pediatric healthcare in the coming years.